


Werner syndrome RecQ helicase-IN-3

Cat. No.:	HY-148740		
CAS No.:	2869954-98-1		
Molecular Formula:	C ₃₁ H ₃₀ ClF ₃ N ₈ O ₅		
Molecular Weight:	687.07		
Target:	DNA/RNA Synthesis		
Pathway:	Cell Cycle/DNA Damage		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 62.5 mg/mL (90.97 mM); ultrasonic and warming and heat to 60°C

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.4555 mL	7.2773 mL	14.5546 mL
	5 mM	0.2911 mL	1.4555 mL	2.9109 mL
	10 mM	0.1455 mL	0.7277 mL	1.4555 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.08 mg/mL (3.03 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (3.03 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (3.03 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Werner syndrome RecQ helicase-IN-3 is a potent and orally active werner syndrome recQ helicase (WRN) inhibitor with an IC₅₀ value of 0.06 μM. Werner syndrome RecQ helicase-IN-3 shows antiproliferative activity. Werner syndrome RecQ helicase-IN-3 shows anticancer activity^[1].

IC₅₀ & Target

IC₅₀: 0.06 μM (WRN)^[1]

In Vitro

Werner syndrome RecQ helicase-IN-3 (example 96) (0-10 μM; 8-20 days) shows antiproliferative activity with GI₅₀s of 0.06,

>10 μ M for SW48, DLD1 WRN-KO cells, respectively^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	SW48, DLD1 WRN-KO cells
Concentration:	0-10 μ M
Incubation Time:	8-20 days
Result:	Showed antiproliferative activity with GI ₅₀ s of 0.06, >10 μ M for SW48, DLD1 WRN-KO cells, respectively.

In Vivo

Werner syndrome RecQ helicase-IN-3 (120 mg/kg; daily for 22 days) shows anticancer activity in mouse^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female Crl:NU(NCr)-Foxn1nu -Homozygous nude mice (SW48 xenografts cells) ^[1]
Dosage:	120 mg/kg
Administration:	P.o.; daily for 22 days
Result:	Inhibited tumor growth.

REFERENCES

[1]. Vincent Bordas, et al. Triazolo-pyrimidine analogues for treating diseases connected to the inhibitor of werner syndrome recq helicase (wrn). WO2022249060A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA